Document Detail

Brain orexin promotes obesity resistance.
Jump to Full Text
MedLine Citation:
PMID:  22803681     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Resistance to obesity is becoming an exception rather than the norm, and understanding mechanisms that lead some to remain lean in spite of an obesigenic environment is critical if we are to find new ways to reverse this trend. Levels of energy intake and physical activity both contribute to body weight management, but it is challenging for most to adopt major long-term changes in either factor. Physical activity outside of formal exercise, also referred to as activity of daily living, and in stricter form, spontaneous physical activity (SPA), may be an attractive modifiable variable for obesity prevention. In this review, we discuss individual variability in SPA and NEAT (nonexercise thermogenesis, or the energy expended by SPA) and its relationship to obesity resistance. The hypothalamic neuropeptide orexin (hypocretin) may play a key role in regulating SPA and NEAT. We discuss how elevated orexin signaling capacity, in the context of a brain network modulating SPA, may play a major role in defining individual variability in SPA and NEAT. Greater activation of this SPA network leads to a lower propensity for fat mass gain and therefore may be an attractive target for obesity prevention and therapy.
Authors:
Catherine Kotz; Joshua Nixon; Tammy Butterick; Claudio Perez-Leighton; Jennifer Teske; Charles Billington
Publication Detail:
Type:  Journal Article; Review     Date:  2012-07-17
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1264     ISSN:  1749-6632     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-13     Completed Date:  2012-10-25     Revised Date:  2014-01-02    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  72-86     Citation Subset:  IM    
Copyright Information:
© 2012 New York Academy of Sciences.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Brain / metabolism*
Energy Metabolism*
Exercise
Humans
Intracellular Signaling Peptides and Proteins / metabolism*
Neuropeptides / metabolism*
Obesity / metabolism*
Rats
Rats, Sprague-Dawley
Rats, Wistar
Signal Transduction
Sleep Stages
Thermogenesis / physiology
Chemical
Reg. No./Substance:
0/Intracellular Signaling Peptides and Proteins; 0/Neuropeptides; 0/orexins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Ann N Y Acad Sci
Journal ID (iso-abbrev): Ann. N. Y. Acad. Sci
Journal ID (publisher-id): nyas
ISSN: 0077-8923
ISSN: 1749-6632
Publisher: Blackwell Publishing Inc, Malden, USA
Article Information
Download PDF
© 2012 New York Academy of Sciences.
open-access:
Print publication date: Month: 8 Year: 2012
Electronic publication date: Day: 17 Month: 7 Year: 2012
Volume: 1264 Issue: 1
First Page: 72 Last Page: 86
ID: 3464355
PubMed Id: 22803681
DOI: 10.1111/j.1749-6632.2012.06585.x

Brain orexin promotes obesity resistance
Catherine Kotz124
Joshua Nixon12
Tammy Butterick12
Claudio Perez-Leighton14
Jennifer Teske56
Charles Billington13
1Department of Veterans Affairs, GRECC and Research ServiceMinneapolis, Minnesota
2Food Science and Nutrition, University of MinnesotaSaint Paul, Minnesota
3Department of Medicine, University of MinnesotaMinneapolis, Minnesota
4Department of Neuroscience, University of MinnesotaMinneapolis, Minnesota
5Department of Nutritional Sciences, University of ArizonaTucson, Arizona
6Research Service, Southern VA Healthcare SystemTucson, Arizona
Correspondence: Address for correspondence: Catherine Kotz, Ph.D., Department of Veterans Affairs-–GRECC and Research Service, One Veterans Drive, Minneapolis, Minnesota 55417. Email: kotzx004@umn.edu
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

Obesity and individual variability

Obesity is a condition defined by a chronic excess of body fat1 and is positively correlated with shorter life expectancy, metabolic syndrome, type 2 diabetes, and coronary heart disease.2 Obesity has become a public health issue, as its incidence in adults and children has increased in the last two decades across both developed and underdeveloped societies.35

Humans show large variation in their susceptibility to obesity, which is determined by both environmental and genetic factors.69 A major factor in determining this variability is physical activity, and specifically a component of overall energy expenditure known as nonexercise induced thermogenesis (NEAT).1012 NEAT includes all forms of energy expenditure not associated with formal exercise, such as standing and fidgeting.10,1315 The complementary concept of spontaneous physical activity (SPA) is used to describe “any type of physical activity that does not qualify as voluntary exercise.”16,17 Both SPA and NEAT have a heredability component.17,18

SPA and NEAT are not interchangeable but are complementary concepts: NEAT refers to energy expenditure while SPA describes the types of physical activity that result in NEAT. Given the association between SPA and NEAT, it is not surprising that variability in SPA also contributes to variability in sensitivity to obesity. For example, lean people spend larger amounts of time standing (approximately two hours daily) than do obese people.12 While the contribution of NEAT to weight gain resistance may seem small, it can be significant. For example, one study showed that after overfeeding humans with 1,000 kcal daily for eight weeks, fat mass gain was significantly and negatively correlated with the increase in SPA and NEAT. Importantly, there was no change in volitional exercise, and no relationship between the observed change in fat mass and basal metabolism or postprandial thermogenesis.11

The neural mechanisms that underlie human variability in SPA are distributed processes involving multiple brain regions, neurotransmitters and neuropeptides, including cholecystokinin, corticotrophin releasing hormone, neuromedin, neuropeptide Y (NPY), leptin, and orexin (also known as hypocretin).19 While all are important, in this review we focus on the biological role of central orexin peptides and their receptors with respect to their role in obesity and obesity resistance.


Orexin peptides and their receptors

The orexins are two closely related peptides, orexin A (OXA, hypocretin 1) and orexin B (OXB, hypocretin 2) that are produced by cleavage from a single propeptide.20,21 In mammals, the majority of CNS orexin peptides are synthesized in neurons located in the lateral hypothalamus and perifornical area. The hypothalamic orexin neurons are glutamatergic neurons with tonic firing, low-threshold spike on recovery from hyperpolarization and little spike adaptation.22,23 Recently, the existence of orexin neuronal subpopulations has been proposed based on morphological and electrophysiological evidence.24

The orexin peptides act through two G protein-coupled receptors, orexin receptor type 1 (OX1R, hypocretin receptor 1) and orexin receptor type 2 (OX2R, hypocretin receptor 2).20,21 Both orexin receptor subtypes can bind to OXA and OXB, but with differential affinity: OX1R has a higher affinity for OXA, while OX2R has equal affinity for either orexin peptide.20,25 Activation of both receptor subtypes leads to an increase in neuronal firing and an increase in intracellular calcium.2630 Preadministration of the OX1R antagonist SB334867 can block OXA-induced SPA and NEAT,16,3134 suggesting an important role for OX1R in mediating SPA and NEAT; however, OX2R involvement has not been ruled out.

An important characteristic of the orexin neurons are their projections to multiple brain regions.3539 Neuroanatomical studies have shown that the orexin neurons have collateral projections within the CNS,4042 transsynaptically collateral CNS efferents,43 or collateral efferents to both CNS regions and brown adipose tissue.44 The distribution pattern of the orexin receptors reflects the widespread projections of orexin neurons, as both orexin receptor subtypes are expressed throughout the brain. The orexin receptors show distinctive, yet overlapping patterns of expression, with a good agreement between mRNA and protein data.4550 However, studies addressing colocalization of the orexin receptor subtypes at a cellular level are lacking. The wide distribution of the orexin receptors and orexinergic fibers initially suggested the orexin system was involved in multiple physiological processes, and current research supports a role for orexin in the control of arousal and sleep, reward, stress, and energy homeostasis.5156

The main contribution of the orexin peptides to energy metabolism is elegantly exemplified in a mouse model that exhibits postnatal loss of orexin neurons.57 In these mice, the orexin promoter drives expression of the neurodegenerative gene ataxin-3, leading to progressive loss of the orexin neurons during development. These mice exhibit hypophagia, lower levels of SPA, and develop spontaneous onset obesity when fed a regular diet.57,58 These results suggest that one primary function of the orexin peptides is to drive energy expenditure, although they can also modulate food intake. Additional support for this idea comes from another mouse model in which the β-actin cytomegalovirus promoter drives overexpression of the orexin peptides.59 Consistent with the role of orexin in promoting energy expenditure, these mice show resistance to high-fat diet–induced obesity.60


Orexin-mediated signaling

As discussed above, the orexin peptides exert their effects by binding to two closely related G protein-coupled receptors. In vitro and in vivo models show that orexin signaling is of an excitatory nature at the cellular level. Increased intracellular Ca2+ influx has been accepted as the most immediate cellular response to orexin receptor activation in both overexpression and in vivo models.25 Signaling responses for orexin receptors and their specific G-α subunit activation are currently under intense investigation. The activation of either orexin receptor can be coupled to Gq, Gi/o, or Gs G-α subunit proteins, which can modulate ion channels and exchangers to induce neuronal depolarization.28,6170 Thus far, increased cellular activity by either OX1R and OX2R can be mediated by modulation of nonselective cationic currents (NSCC), voltage-gated calcium channels, the Na+/Ca2+ exchanger, and inwardly rectifying potassium channels.27,28,30,7179

The type of intracellular mechanism triggered by activation of the receptors appears to be cell dependent. For example, in nucleus accumbens and nucleus of the solitary tract, OX1R/OX2R mediated depolarization requires a simultaneous decrease in K+ conductance and increase in NSCC.26,73 In GABAergic neurons from the arcuate nucleus, it occurs through a decrease in K+ conductance and activation of the Na+/Ca2+ exchanger.80 Finally, there are differences in the temporal profile of intracellular Ca2+ increases after OX1R/OX2R activation between neurons from the dorsal raphe and laterodorsal tegmental areas.29,81

The specific mechanisms involved in orexin mediated second messenger cascades, and their physiological relevance to obesity, are relatively undefined. Homogeneous overexpression models with human OX1R have revealed alterations in adenylyl cyclase activity via Gi/o, Gs, and Gq subunits but differ in their potency.25,61 OXA can also activate extracellular signal-regulated kinases (ERK1/2) and p38 mitogen-activated phosphate kinase (MAPK) in recombinant and adrenal cell culture models.82 OXA activation of either OX1R/OX2R in cells overexpressing either receptor can elicit the activation of ERK1/2 and p38 MAPK via multiple G-α subunits.70 Food deprivation in Wistar rats has also revealed differences in G-α subunit activation in hypothalamic tissue homogenates in response to OXA.83 However, discrete hypothalamic OXA-induced G-α subunit signaling responses for either OX1R or OX2R have yet to be determined when coexpressed.

The relevance of OX1R/OX2R in obesity has been exemplified in the obesity resistant (OR) and obesity prone (OP) rats. OR rats have higher basal levels of both intrinsic SPA and OXA-induced SPA following injections into the rostral lateral hypothalamic area (rLH) than OP or Sprague Dawley rats.34 Increased OXA sensitivity in OR rats appears to be due to an increase in receptor abundance compared to OP rats. While a difference in receptor density may address OXA sensitivity in OR rats, receptor functionality may also help explain the influence of orexin on SPA. Some aspects of orexin receptor sensitivity, distribution, and intracellular signaling mechanisms important in mediating OXA effects on SPA are currently under investigation using the OP or OR rat and other polygenic models of obesity. One such possibility under investigation is that that rLH orexin receptors in OR rats couple to Gs rather than Gi/o proteins, while the opposite occurs in OP rats.


Orexin in an animal model of obesity resistance

Levin et al. showed that when fed a high-fat diet a tertile of outbred Sprague Dawley rats gained no more weight than chow-fed controls.84 These diet-induced obese rats and their weight-gain resistant counterparts, referred to as diet resistant, were selectively bred by a commercial vendor for over ten years,85,86 resulting in the current OP/OR polygenic model of obesity. The OP and OR rats have divergent weight gain profiles despite inconsistently observed differences in energy intake.34,85,86 While early studies demonstrated that obese rats had a dampened feeding response to satiety-promoting agents such as leptin87 and insulin,88 it was clear that other neural modulators as well as differences in SPA likely contributed to the polygenic obesity observed in OR and OP rats. As the orexins modulate SPA,31,32,89 these findings underscored the potential significance of orexin as a neural modulator regulating body weight in this rodent model.

Like the outbred diet-resistant rats, the selectively bred OR rats exhibit lower body weight and fat mass gain on a low-fat diet and gain less weight when fed high-fat diet relative to their obesity-prone counterparts.33,34,85,90 These OR rats consume significantly fewer absolute calories, but they consume statistically more calories when calculated on a per gram body mass basis.34 Differences in SPA between OP and OR rats suggested by an early study91 were confirmed by tracking SPA levels in several groups of OP and OR rats at various ages using a chamber that tracks activity in the x, y, and z axes using infrared beams.34,90,92,93 OR rats display more ambulatory and vertical movement independent of age or the presence of food,34,90,92 and this finding has been consistent across different groups of OR and OP rats.92 Subsequent studies revealed that this greater SPA was associated with greater energy expenditure,92 a lower propensity to gain fat mass throughout development, maturation, and aging,90 and maintenance of higher SPA levels after high-fat diet feeding.33

OXA-induced SPA is associated with a dose-dependent increase in energy expenditure.31 Together with our previous studies showing OXA-induced hyperphagia following rLH infusion,94,95 we hypothesized that heightened responses to SPA-promoting agents and a dampened response to feeding-stimulatory agents such as OXA would perpetuate the lean phenotype in OR rats. To test this, OR and OP rats with chronically implanted guide cannulae targeting the rLH were given graded doses of OXA. In separate experiments, SPA and food intake were measured postinjection in young and adult rats. As expected, OR rats had greater OXA-induced SPA independent of age,34 but OR rats also had greater OXA-induced food intake per gram body mass than OP rats (also independent of age).34 This increase in caloric intake fits with the above-described enhanced 24 hour basal caloric intake in OR versus OP rats, and the idea that any behavioral effect of OXA in OR rats may be heightened due to higher OXA signaling capacity in OR rats (described in more detail below). OR rats maintain a lean phenotype over time, suggesting that the negative caloric benefit of OXA-induced SPA appears to outweigh the positive calories due to OXA-induced hyperphagia. A potential contributing mechanism for this is the observed longer duration of OXA action on SPA relative to that on food intake.89 Further supporting the idea that OR rats have higher endogenous SPA, we later showed that OR rats are also more sensitive to other SPA-promoting stimuli including caloric restriction96 and appear to be intrinsically protected from treatments that lower SPA, such as high-fat diet feeding. We and others have shown that in contrast to OP rats, which display lower SPA levels after high-fat diet consumption, OR rats maintain high basal SPA levels and have greater OXA-induced SPA after high fat diet feeding.97 Most importantly, we also showed that rLH-OXA increases energy expenditure,93 and others found that daily OXA treatment reduces body weight by increasing SPA.98 These findings support the hypothesis that elevated energy expenditure due to SPA-promoting agents such as OXA and defense from SPA-dampening treatments protects against excessive adiposity gain in OR rats.

To understand whether differences in responsivity to OXA are driven by greater orexin signaling at the level of the peptide or the receptor, we analyzed mRNA data for prepro-orexin, OX1R, and OX2R from brain micropunches in OR and OP rats. Our data show that relative to OP rats, OR rats have greater orexin receptor mRNA in the rLH despite similar levels of preproorexin in the rLH or within whole hypothalamus.34 This elevated receptor mRNA is mirrored by elevated receptor peptide levels in OR rats (Fig. 1). We later showed greater orexin receptor mRNA in the dorsal raphe, locus coeruleus, and ventrolateral preoptic area, in addition to better sleep quality in OR rats, which would be expected to contribute to the favorable weight status observed.99 Together with our earlier work, these data suggest that elevated orexin receptor mRNA within distinct brain sites function to create a brain-wide orexin signaling network at the level of the receptor that perpetuates heightened basal and OXA-stimulated SPA levels, which attenuates adiposity gain in OR rats.

There are many animal models developed to amplify divergent locomotor activity, wheel running, or aerobic capacity.17,100 These models help clarify the role of overall physical activity level in obesity, but they do not mirror models varying in SPA, as exercise has been shown to have a strong motivational component, whereas SPA may not. A recent series of studies undertaken by Novak et al.101,102 in rodents selectively bred for high and low wheel running capacity (HCR and LCR, respectively)103 have shown that HCR rats also have greater SPA, and basal and activity-induced energy expenditure.102 Furthermore, like OR rats, HCR rats have heightened SPA following OXA infusion in the hypothalamic PVN.101 However, in contrast to OR rats, greater OXA-induced SPA in HCR rats is accompanied by greater OXA content but not increased orexin receptor mRNA in the perifornical lateral hypothalamus.101

It is possible that the differences in orexin function between animal models bred for high exercise and the OP and OR rats arise from long-term effects of high fat consumption in this particular model. In itself, this makes the OP and OR rats a more appropiate model for studies of diet-induced obesity. The evidence from the OP and OR model suggests that the interaction between high fat consumption and the orexins is determined by individual susceptibility to high fat consumption, which in turn might be determined by baseline orexin signaling through particular brain regions, including the rLH. In summary, while animal models of high exercise may share some of the same orexin signaling characteristics as that of high SPA models, there are likely differences in the regulatory control of orexin between these models, which might be a consequence of the high-fat intake used to derive the OP and OR rats.


Orexin and sleep

As mentioned above, OR rats, with higher orexin signaling capacity, also exhibit more consolidated sleep relative to OP rats. The overall distribution of orexin fibers in the brain has suggested that the orexins play a role in a number of systems, including the maintenance of arousal.104,105 Orexin fibers have been shown to project to several brain nuclei implicated in the control of sleep state.3539 Application of OXA in the locus coeruleus104,106 and lateral preoptic area107 of the rat increase wakefulness, primarily through a decrease in rapid eye movement (REM) sleep.106 Activity in locus coeruleus (LC) neurons increases following application of OXA.104106 More recently, direct stimulation of electrical activity in orexin neurons using optogenetic techniques was shown to induce wakefulness in sleeping mice.108

In addition to projecting to sleep-wake nuclei, orexin cells receive input from brain systems involved in regulation of sleep-wakefulness. In mammals, circadian organization of activity including sleep-wake behavior is regulated by the endogenous clock located in the suprachiasmatic nucleus (SCN).109 Orexin cell bodies receive both limited direct contact from the SCN,110 as well as substantial indirect contact from the SCN via the medial preoptic area and the subparaventricular zone.111,112 Orexin neurons show circadian patterns of activation,113 and ablation of the SCN eliminates rhythmicity of orexin release.114 Introduction of chemicals known to increase arousal in rats, such as methamphetamines or the anti narcoleptic drug modafanil, increase nuclear Fos expression in orexin cell bodies.115,116 Furthermore, increasing the behavioral arousal of rats by sleep deprivation induced due to handling also increases the expression of nuclear Fos in OXA cells.116 Finally, in a diurnal rodent model, Fos expression patterns in orexin neurons are correlated with individual variation in the timing of daily wheel running activity.117 The orexins thus appear to be capable of both receiving information related to the arousal state of the animal, and relaying arousal information to other nuclei known to promote wakefulness.

The association between the orexins and arousal was strengthened by the discovery that sleep disorder narcolepsy is associated with a defect in the orexin system.57,115 While it is clear from this evidence that orexin is not necessary for wakefulness, data suggest that orexin is important in maintaining high levels of arousal, and that one major function of the orexin system is to stabilize sleep–wake transitions. Furthermore, there is a recognition that orexin activity may be incompatible with sleep, as direct activation of orexin neurons causes wakefulness in rodents,108 and silencing of orexin neuronal activity during the inactive period results in slow wave sleep.118

Two comorbidities associated with narcolepsy—cataplexy and obesity—help shed light on the importance of orexin in normal physiology. Early studies of orexin effects suggested that orexin results in the activation of motor activity,119,120 and it is well established that physical activity is correlated with both activation of orexin neurons 116,117 and increases in OXA release.121 In narcoleptic individuals, cataplexy (defined as a loss of muscle tone) is often triggered by emotional stress or physical exertion,122 and is preceded by a reduction of neuronal firing in the LC.123 Injection of OXA into the locus coeruleus activates LC neurons104106 and increases muscle tone.124 Promotion of motor activity may thus be one important function of orexin, and this orexin-induced activity may be coupled strongly to behavioral state to maintain normal motor tone during periods of emotional or physical stress.

Obesity is a comorbidity of narcolepsy in both human and animal models.57,122,125 Both human and animal subjects with narcolepsy eat less as would be expected given the association between orexins and feeding behavior.57,125 Yet the effect of reduced caloric consumption is offset by decreases in physical activity, as narcoleptic individuals exhibit a significantly elevated body mass index relative to nonnarcoleptic patients.122 In human subjects, while the total time spent awake is not reduced, there is a decreased amplitude of circadian activity patterns, consistent with reduced overall physical activity.126 In a mouse model of narcolepsy, in which orexin neurons are ablated postnatally, physical activity during the active (but not the resting) phase is reduced in affected animals,57 and these animals subsequently become obese. These human and animal studies demonstrate that the effects of orexin on sleep–wake patterns and physical activity are consistent with the idea that orexin is a neuropeptide conveying resistance to obesity.

Instability of sleep patterns is known to contribute to weight gain.127,128 In this light, it could be argued that weight gain in narcolepsy is more due to disturbance of sleep than to reductions in activity due to lack of orexin signaling. However, evidence from a diurnal rodent model and from laboratory rats suggests that orexin-associated activity can be altered without disturbing total sleep. Wheel running activity in some Nile grass rats can occur exclusively at night, during the inactive phase, while in others wheel running follows the normal diurnal pattern.129 While Fos activation in orexin neurons occurs only during the light period in day-active animals, in night-active grass rats Fos is elevated both during nightly activity bouts and during the day.117 Behavioral measures of sleep in these animals showed that while the timing of sleep was changed in night-active animals due to wheel running at night, neither total sleep nor duration of sleep bouts differed between groups.130 Finally, previously unpublished data from our laboratory show that in OP and OR rats the effects of orexin on activity and arousal are not inextricably linked. Application of exogenous orexin significantly increases physical activity in OR relative to OP rats; however, recordings of total sleep using implanted EEG/EMG transmitters showed that this increase in activity was not caused by increased arousal or reduced sleep time in OR rats (Fig. 2). Importantly, while both sets of rats had increased time spent in wakefulness, there was not a greater increase in OR rats relative to OP rats. This lack of difference between OP and OR rats in time spent awake after orexin treatment suggests that SPA following orexin is not merely due to increased wakefulness; the SPA effect in OR rats is in addition to the wake-promoting effect of orexin.


Translating SPA to energy expenditure

An important consideration is the relevance of SPA to overall energy expenditure. Energy expenditure (EE) comprises at least four main components, including basal metabolic rate (BMR; 60–70% of EE), which is the minimal energy required to maintain life, including heart beat, respiration, endocrine secretion, and kidney filtration. Diet-induced thermogenesis constitutes about 10% of total EE and includes energy related to the digestion, absorption, and metabolism of foods. Adaptive thermogenesis ranges from 10% to 15% of total EE and is related to adjustments in energy expenditure due to environment changes (e.g., shivering). Physical activity is the most variable of these components, ranging from 6% to 10% of total EE.131

SPA is neither a part of BMR nor a part of exercise physical activity. Therefore, it may be an attractive obesity target. SPA in humans was identified as early as 1954, and defined as a component of energy expenditure.132 Ravussin et al.15 showed that SPA in a human respiratory chamber averaged 348 kcal/day and, importantly, identified a large range in values: 100–700 kcal/day. Clearly, this wide range in values among humans suggests that there could be a large range in the weight gain response to overfeeding in humans, as demonstrated by Levine et al.11 Zurlo et al.133 showed that levels of SPA clustered in families, and could prospectively help explain propensity for weight gain in males, which suggests heritability of SPA. As discussed above, the idea that SPA level is an intrinsic heritable trait has recently been strengthened by Levine et al., in his study showing that lean humans stand and ambulate for approximately two hours daily more than obese, which is not affected by weight loss or weight gain, in the obese and lean respectively.11 That spontaneous physical activity levels differ between mouse strains134 also suggests that SPA is an intrinsic, inherited trait that varies within animal species.

Despite large differences in body fat, energy intake, and body size, OR and OP rats expend a similar number of absolute kilocalories.92 This suggests that OR rats are less efficient in their calorie use, as they are expending relatively large amounts of calories to support their relatively smaller energy needs related to their reduced body circumference and body fat, which affect levels of heat loss. This supports the idea that elevated SPA and the resultant NEAT in OR rats contributes to their obesity resistant phenotype.34

When considering the therapeutic potential of SPA, a practical consideration is the comparability of the SPA difference between OP and OR rats to that in obesity-prone versus obesity-resistant humans. Calories expended via spontaneous physical activity correlate with whole body energy expenditure in humans and in animals.14,92 However, are the extra calories mediated by SPA in an OR rat, when compared to that in humans, enough to make meaningful changes in body weight? Based on indirect calorimetry studies, we estimate the energy flux in a rat to be about 100 kcal/day; SPA differences between OP and OR rats, when corrected for lean mass, amount to about 4 kcal/day or 4%.92 In humans, a 100 kcal energy gap (that level of energy intake above the daily requirement to maintain a stable body weight) per day, or 5% for a person in balance at 2,000 kcal/day, can lead to a 10-lb weight differential over one year.135 Based on this synthesis, we conclude that it is clear that SPA differences explaining obesity resistance in rodents can be relevant for human body weight control. Further, orexin-mediated mechanisms identified here may explain the differential body weight gain response to overfeeding in humans.11 For example, a prior human study showed that gain or loss of 10–20 pounds resulted in linear changes in energy expenditure, and that the majority of the change was specifically in nonresting energy expenditure (i.e., NEAT).136 We know that physical activity is correlated with both activation of orexin neurons116,117 and increases in OXA release,121 although the pathways through which this is effected are largely undefined. Thus increased SPA (either endogenous or artificial) could also lead to feedback mechanisms that maintain higher SPA levels in the future.

As discussed elsewhere in this review, orexin enhances feeding behavior and physical activity in a site-specific manner, with some sites conveying information regarding eating behavior, others activity, yet others both or neither. As our data and others show, the energetic consequence of these two behavioral outputs, when added up on a caloric basis, may result in negative energy balance and reduce body weight. In other words, the calories taken in by the effects of the orexin signal are outweighed by those expended via physical activity.


Networks regulating spontaneous physical activity

Orexin plays a key role in an interdependent distributed brain network that regulates spontaneous physical activity. A significant number of brain sites that participate in this regulatory network in the forebrain and hindbrain have been identified, and there are a number of neurotransmitters that participate in this network, as depicted in Figure 3. The SPA network is distinct from the brain pathways that regulate purposeful activity, although the final common pathway leading to movement is clearly shared. Many of the brain sites that participate in the SPA network also participate in regulatory networks for food intake and other aspects of energy balance such as thermogenesis, but based both on distribution and on functional responses to stimulation, including orexin stimulation, it is clear that the SPA network is different from the networks that otherwise regulate energy balance.

Orexin is a unique contributor to this distributed SPA regulatory network by virtue of its position and projections. Orexin is made in one relatively small area of the hypothalamus, involving the caudal lateral hypothalamus and adjacent perifornical area.20,21 From these sites, orexin projects throughout the brain. Orexin neurons project throughout the hypothalamus, including the paraventricular, arcuate, rostrolateral, perifornical, and ventromedial areas, as well as to several extrahypothalamic sites, including the septal nuclei, bed nucleus of the stria terminalis, paraventricular, and reunions nuclei of the thalamus, zona incerta, subthalamic nucleus, central gray, substantia nigra, dorsal raphe nuclei, parabrachial nucleus, locus coeruleus, medullary reticular formation, area postrema, and nucleus of the solitary tract.92

The sites receiving orexin signal vary considerably with respect to the primary function associated with that site.53 Further, it is likely that in many sites the orexin effect on SPA is partially overlapping with other known orexin actions such as attention and wakefulness. While the functional outcomes of orexin action vary considerably from site to site, the production of SPA is common across many sites, and is widely distributed.92 This organization, involving a focused site of origin with wide distribution of effect, greatly enhances the potential potency of orexin as a regulator of spontaneous physical activity.

Orexin neurons receive input from a number of sites throughout the brain that are thought to influence expression of the orexin signal. The lateral hypothalamus receives afferents from cortical structures, including the prefrontal/orbitofrontal, insular, and olfactory cortices; limbic sites, including the amygdala, the hippocampal formation, and the shell of the nucleus accumbens; and from brainstem sites, including the nucleus of the solitary tract.137 Projections from other parts of hypothalamus include those from arcuate nucleus proopiomelanocortin (POMC)/cocaine and amphetamine-related transcript (CART) and NPY/agouti-related protein (AgRP) neurons.138,139 In addition, there is connectivity within the lateral hypothalamic area, notably projections from anterior to posterior portions.140 Whether all of these lateral hypothalamic projections play a significant role in regulating the activity of orexin neurons specifically is not yet determined, but a strong network of local lateral hypothalamic interneurons indicates the possibility of influences even by projections that do not directly synapse on orexin neurons themselves.140 Tracing studies have specifically identified projections to lateral hypothalamic orexin neurons from several regions of the amygdala, nucleus accumbens shell, bed nucleus of the stria terminalis, laterodorsal tegmental area, basal forebrain cholinergic neurons, GABAergic neurons in the preoptic area, and serotonergic neurons in the median/paramedian raphe nuclei.138

Orexin neurons are in a baseline intrinsic state of depolarized activity141 and are highly influenced by local conditions in an intralateral hypothalamic local network.140 The functional effects of the many afferents, and the associated neural function and neurotransmitters to orexin neurons, are underexploration. Application of the cholinergic agent carbachol activates many orexin neurons, indicating that the cholinergic input to orexin neurons from basal forebrain is excitatory.138 Cholinergic input from the laterodorsal tegmental area may also be excitatory to orexin neurons. Input of an as yet unidentified chemical type from the amygdala and bed nucleus of stria terminalis may also stimulate orexin neurons.138 CRF release from projections originating in the hypothalamic paraventricular nucleus also activates orexin neurons.142 Inhibitory influences on orexin neurons come from the preoptic area and from the serotonergic neurons in the median raphe.138

The physiological conditions that are known to affect orexin neurons include suppression of activity by glucose,143 along with prominent activation by hypoglycemia144 and by food restriction.145 There is evidence that low glucose states may be directly sensed by orexin neurons,143 although the likelihood of low glucose signals originating in other glucose sensing neurons with projections to orexin neurons is substantial. Intracellular Foxa2 signaling from the insulin receptor may be a mechanism allowing orexin neurons to sense the state of glucose and possibly short-term nutrition.146 Orexin neurons also receive local projections from leptin receptor bearing neurons, providing a means for translating the state of leptin signaling to the orexin neurons, and leptin action in lateral hypothalamus increases orexin action and decreases food intake.147 Leptin and energy state sensing arcuate neurons that express POMC/CART and NPY/AgRP also project to lateral hypothalamic neurons.138,139 A recent study has shown that amino acids, particularly nonessential amino acids, can stimulate orexin neurons directly through action on potassium channels and amino acid transporters.148 The stimulation provided by amino acids may be potent enough to overcome inhibition by glucose.148 Additional energy and nutrient related information may come to orexin neurons, perhaps directly, from the gut hormones ghrelin and glucagon-like peptide 1, both of which appear to activate orexin neurons in direct administration studies.120,149 Orexin neurons also receive input about physiological stress–related information, likely through a corticotrophin releasing hormone pathway.142 The integration of nutrition-related and other signals in orexin neurons, or in a network of which orexin is part, has not been defined.

Orexin signaling pathways can be further modified by the level of orexin-receptor expression in brain sites receiving orexin efferents. The conditions that lead to modulation of orexin receptor expression are incompletely defined. One example is the difference in orexin-receptor expression in a variety of brain sites associated with the difference between orexin-induced SPA response in polygenic OP and OR rat strains,90,99 as described elsewhere in this review.

Many brain areas contribute to SPA, and all of these areas operate in a network; thus activity in one area, affected by environmental cues or physiology as discussed above, influences firing patterns in other areas. Behavioral studies of SPA can determine the output of specific brain activity, improving understanding of the brain sites and neurotransmitter systems that are most important. The existing literature, however, is not always interpretable in a straightforward way. Locomotor activity measured in a beam-break chamber (as has been done for SPA measures) has also been used to assess nonspecific drug effects, as in studies of drugs of abuse. Similarly, low locomotor activity has been used as a diagnostic criterion for depression or illness in rats and mice.150 Thus, the data must be interpreted with care and in many cases repeated in a new context for full understanding.

Orexin A injected in almost all brain areas increases SPA, contrasting with feeding behavior that is stimulated after injection into only some of the same sites.92 The time course of action is different for the feeding and activity effects of orexin A, so the presence of one behavior (feeding or SPA) does not depend upon the other.95 Whether OXA-induced SPA is derived from orexin-enhanced wakefulness is not clear, but as discussed elsewhere in this review it appears likely that energy expenditure produced from SPA occurs after the initial waking event.

Many neurotransmitters have been shown to influence SPA in the network into which orexin action is projecting, although most of the available studies reporting on locomotor activity do not directly consider SPA itself, so at present some inferences must be made. Neurotransmitters that are likely to affect SPA include cholecystokinin, corticotrophin releasing hormone, neuromedin, NPY, leptin, and orexin.19 The current state of the evidence does not permit straightforward interpretation of the direction of effect for these neurotransmitters since there is disparate evidence based in part on site and type of administration.19 In general, it appears that in most situations each of these neurotransmitters can stimulate SPA, but orexin is the most consistent across all brain sites and types of stimulation. Little is presently known about the interactions of orexin with these other neurotransmitters with respect to the regulation of SPA.

Ultimately the output pathways for the SPA regulatory network must share engagement of the motor control pathways with voluntary movement brain mechanisms. The brain locations where these movement regulatory pathways begin to overlap have not yet been defined. It is likely that in part there are projections from forebrain structures, including the hypothalamus, to spinal motor neurons. An interesting possibility is that the SPA regulatory network engages cortical areas involved in voluntary motor control. The wide pattern of projections of the orexin neurons throughout the brain could mediate this function. In addition, a projection pathway from the accumbens through cortical premotor neurons and out to the spinal motor neurons has also been implicated.92


Conclusion

Brain mechanisms mediate SPA and NEAT (Fig. 3), and the understanding of this concept is beginning to shed light on new ways to target obesity prevention and treatment. Studies of orexin and its role in obesity resistance show that stimulation of orexin receptors may be an attractive therapy for altering the course of excess body weight gain with aging, and also demonstrate that modulating SPA and NEAT has important consequences for obesity resistance. The knowledge of this can guide human obesity therapy immediately, as the option to include more low-level activity throughout one's day is likely more feasible advice to prevent and treat obesity than standard approaches that repeatedly fail over time. The greater challenge is in how to use information on brain SPA and NEAT networks to provide better pharmaceutical and/or other therapeutic approaches for treatment of obesity. The rapid development of new neurochemical methods of altering brain neurophysiology and recent advances in computer/brain interface technologies provide confidence that knowledge of brain SPA and NEAT networks could be therapeutically applied in the near future.


Conflicts of interest

The authors declare no conflicts of interest.


References
1. Berthoud HR,Morrison C. The brain, appetite, and obesityAnnu. Rev. PsycholYear: 200859559218154499
2. Must A,et al. The disease burden associated with overweight and obesityJAMAYear: 19992821523152910546691
3. Wang Y,Lobstein T. Worldwide trends in childhood overweight and obesityInt. J. Pediatr. ObesYear: 20061112517902211
4. Ogden CL,et al. Prevalence of overweight and obesity in the United States, 1999–2004JAMAYear: 20062951549155516595758
5. Flegal KM,et al. Prevalence and trends in obesity among US adults, 1999–2008JAMAYear: 201030323524120071471
6. Bouchard C,et al. The response to long-term overfeeding in identical twinsN. Engl. J. MedYear: 1990322147714822336074
7. Forbes GB,et al. Deliberate overfeeding in women and men: energy cost and composition of the weight gainBr. J. NutrYear: 198656193479191
8. Mustelin L,et al. Physical activity reduces the influence of genetic effects on BMI and waist circumference: a study in young adult twinsInt. J. ObesYear: 2009332936
9. Hamilton MT,Hamilton DG,Zderic TW. Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular diseaseDiabetesYear: 2007562655266717827399
10. Levine JA. Non-exercise activity thermogenesis (NEAT)Best Pract. Res. Clin. Endocrinol. MetabYear: 20021667970212468415
11. Levine JA,Eberhardt NL,Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humansScienceYear: 19992832122149880251
12. Levine JA,et al. Interindividual variation in posture allocation: possible role in human obesityScienceYear: 200530758458615681386
13. Fruhbeck G. Does a NEAT difference in energy expenditure lead to obesity?LancetYear: 200536661561616112286
14. Ravussin E. Physiology. A NEAT way to control weight?ScienceYear: 200530753053115681373
15. Snitker S,Tataranni PA,Ravussin E. Spontaneous physical activity in a respiratory chamber is correlated to habitual physical activityInt. J. Obes. Relat. Metab. DisordYear: 2001251481148611673770
16. Kotz CM,et al. Orexin A mediation of time spent moving in rats: neural mechanismsNeuroscienceYear: 2006142293616809007
17. Garland T Jr,et al. The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectivesJ. Exp. BiolYear: 201121420622921177942
18. Dishman RK. Gene-physical activity interactions in the etiology of obesity: behavioral considerationsObesityYear: 200816Suppl 3S60S6519037216
19. Teske JA,Billington CJ,Kotz CM. Neuropeptidergic mediators of spontaneous physical activity and non-exercise activity thermogenesisNeuroendocrinologyYear: 200887719017984627
20. Sakurai T,et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviorCellYear: 1998925735859491897
21. de Lecea L,et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activityProc. Natl. Acad. Sci. USAYear: 1998953223279419374
22. Burdakov D,Gerasimenko O,Verkhratsky A. Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situJ. NeurosciYear: 2005252429243315745970
23. Li Y,et al. Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal systemNeuronYear: 2002361169118112495630
24. Schone C,et al. Dichotomous cellular properties of mouse orexin/hypocretin neuronsJ. PhysiolYear: 20115892767277921486780
25. Ammoun S,et al. Distinct recognition of OX1 and OX2 receptors by orexin peptidesJ. Pharmacol. Exp. TherYear: 200330550751412606634
26. Yang B,Ferguson AV. Orexin-A depolarizes nucleus tractus solitarius neurons through effects on nonselective cationic and K+ conductancesJ. NeurophysiolYear: 2003892167217512611968
27. van den Pol AN,et al. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexinJ. NeurosciYear: 199818796279719742163
28. Larsson KP,et al. Orexin-A-induced Ca2+ entry: evidence for involvement of trpc channels and protein kinase C regulationJ. Biol. ChemYear: 20052801771178115537648
29. Uramura K,et al. Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2 +signaling in dopamine neurons of the ventral tegmental areaNeuroreportYear: 2001121885188911435917
30. Follwell MJ,Ferguson AV. Cellular mechanisms of orexin actions on paraventricular nucleus neurones in rat hypothalamusJ. PhysiolYear: 200254585586712482891
31. Kiwaki K,et al. Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in ratsAm. J. Physiol. Endocrinol. MetabYear: 2004286E55155914656716
32. Kotz CM,et al. Feeding and activity induced by orexin A in the lateral hypothalamus in ratsRegul. PeptYear: 2002104273211830273
33. Novak CM,Kotz CM,Levine JA. Central orexin sensitivity, physical activity, and obesity in diet-induced obese and diet-resistant ratsAm. J. Physiol. Endocrinol. MetabYear: 2006290E39640316188908
34. Teske JA,et al. Elevated hypothalamic orexin signaling, sensitivity to orexin A, and spontaneous physical activity in obesity-resistant ratsAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2006291R88989916763079
35. Date Y,et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systemsProc. Natl. Acad. Sci. USAYear: 1999967487539892705
36. Mintz EM,et al. Distribution of hypocretin-(orexin) immunoreactivity in the central nervous system of Syrian hamsters (Mesocricetus auratus)J. Chem. NeuroanatYear: 20012122523811382534
37. Moore RY,Abrahamson EA,Van Den Pol A. The hypocretin neuron system: an arousal system in the human brainArch. Ital. BiolYear: 200113919520511330201
38. Nixon JP,Smale L. A comparative analysis of the distribution of immunoreactive orexin A and B in the brains of nocturnal and diurnal rodentsBehav. Brain FunctYear: 200732817567902
39. Peyron C,et al. Neurons containing hypocretin (orexin) project to multiple neuronal systemsJ. NeurosciYear: 1998189996100159822755
40. Espana RA,et al. Organization of hypocretin/orexin efferents to locus coeruleus and basal forebrain arousal-related structuresJ. Comp. NeurolYear: 200548116017815562511
41. Ciriello J,et al. Identification of neurons containing orexin-B (hypocretin-2) immunoreactivity in limbic structuresBrain ResYear: 200396712313112650973
42. Krout KE,Mettenleiter TC,Loewy AD. Single CNS neurons link both central motor and cardiosympathetic systems: a double-virus tracing studyNeuroscienceYear: 200311885386612710992
43. Geerling JC,Mettenleiter TC,Loewy AD. Orexin neurons project to diverse sympathetic outflow systemsNeuroscienceYear: 200312254155014614918
44. Oldfield BJ,et al. Lateral hypothalamic ‘command neurons’ with axonal projections to regions involved in both feeding and thermogenesisEur. J. NeurosciYear: 2007252404241217445237
45. Cluderay JE,Harrison DC,Hervieu GJ. Protein distribution of the orexin-2 receptor in the rat central nervous systemRegul. PeptYear: 200210413114411830288
46. Greco MA,Shiromani PJ. Hypocretin receptor protein and mRNA expression in the dorsolateral pons of ratsBrain Res. Mol. Brain ResYear: 20018817618211295245
47. Hervieu GJ,et al. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cordNeuroscienceYear: 200110377779711274794
48. Marcus JN,et al. Differential expression of orexin receptors 1 and 2 in the rat brainJ. Comp. NeurolYear: 200143562511370008
49. Sunter D,et al. Orexins: effects on behavior and localisation of orexin receptor 2 messenger ribonucleic acid in the rat brainstemBrain ResYear: 2001907273411430882
50. Trivedi P,et al. Distribution of orexin receptor mRNA in the rat brainFEBS LettYear: 199843871759821961
51. Berridge CW,Espana RA,Vittoz NM. Hypocretin/orexin in arousal and stressBrain ResYear: 201013149110219748490
52. Harris GC,Aston-Jones G. Arousal and reward: a dichotomy in orexin functionTrends NeurosciYear: 20062957157716904760
53. Kotz CM. Integration of feeding and spontaneous physical activity: role for orexinPhysiol. BehavYear: 20068829430116787655
54. Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasisSleep Med. RevYear: 2005923124115961331
55. Sharf R,Sarhan M,Dileone RJ. Role of orexin/hypocretin in dependence and addictionBrain ResYear: 2010131413013819699189
56. Tsujino N,Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward systemPharmacol. RevYear: 20096116217619549926
57. Hara J,et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesityNeuronYear: 20013034535411394998
58. Akiyama M,et al. Reduced food anticipatory activity in genetically orexin (hypocretin) neuron-ablated miceEur. J. NeurosciYear: 2004203054306215579160
59. Mieda M,et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in miceProc. Natl. Acad. Sci. USAYear: 20041014649465415070772
60. Funato H,et al. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivityCell MetabYear: 20099647619117547
61. Ammoun S,et al. OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signalingMol. EndocrinolYear: 200620809916141359
62. Ekholm ME,Johansson L,Kukkonen JP. IP3-independent signalling of OX1 orexin/hypocretin receptors to Ca2+ influx and ERKBiochem. Biophys. Res. CommunYear: 200735347548017188243
63. Johansson L,Ekholm ME,Kukkonen JP. Regulation of OX1 orexin/hypocretin receptor-coupling to phospholipase C by Ca2 +influxBr. J. PharmacolYear: 20071509710417115071
64. Johansson L,Ekholm ME,Kukkonen JP. Multiple phospholipase activation by OX(1) orexin/hypocretin receptorsCell Mol. Life SciYear: 2008651948195618488139
65. Kukkonen JP,Akerman KE. Orexin receptors couple to Ca2+ channels different from store-operated Ca2+ channelsNeuroreportYear: 2001122017202011435939
66. Lund PE,et al. The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase CJ. Biol. ChemYear: 2000275308063081210880509
67. Magga J,et al. Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1Biochem. PharmacolYear: 20067182783616430869
68. Nasman J,et al. The orexin OX1 receptor regulates Ca2+ entry via diacylglycerol-activated channels in differentiated neuroblastoma cellsJ. NeurosciYear: 200626106581066617050705
69. Peltonen HM,et al. Involvement of TRPC3 channels in calcium oscillations mediated by OX(1) orexin receptorsBiochem. Biophys. Res. CommunYear: 200938540841219464259
70. Tang J,et al. The signalling profile of recombinant human orexin-2 receptorCell SignalYear: 2008201651166118599270
71. Hoang QV,et al. Effects of orexin (hypocretin) on GIRK channelsJ. NeurophysiolYear: 20039069370212702704
72. Hoang QV,et al. Orexin (hypocretin) effects on constitutively active inward rectifier K +channels in cultured nucleus basalis neuronsJ. NeurophysiolYear: 2004923183319115269229
73. Mukai K,et al. Electrophysiological effects of orexin/hypocretin on nucleus accumbens shell neurons in rats: an in vitro studyPeptidesYear: 2009301487149619416746
74. van den Pol AN,et al. Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleusJ. PhysiolYear: 200254116918512015428
75. Samson WK,et al. Orexin actions in hypothalamic paraventricular nucleus: physiological consequences and cellular correlatesRegul. PeptYear: 20021049710311830283
76. Burlet S,Tyler CJ,Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by Hypocretin/Orexin peptides: implications for wakefulness and narcolepsyJ. NeurosciYear: 2002222862287211923451
77. Bayer L,et al. Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neuronsJ. NeurosciYear: 2002227835783912223534
78. Bisetti A,et al. Excitatory action of hypocretin/orexin on neurons of the central medial amygdalaNeuroscienceYear: 2006142999100416996221
79. Liu RJ,van den Pol AN,Aghajanian GK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actionsJ. NeurosciYear: 2002229453946412417670
80. Burdakov D,Liss B,Ashcroft FM. Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium–calcium exchangerJ. NeurosciYear: 2003234951495712832517
81. Kohlmeier KA,Inoue T,Leonard CS. Hypocretin/orexin peptide signaling in the ascending arousal system: elevation of intracellular calcium in the mouse dorsal raphe and laterodorsal tegmentumJ. NeurophysiolYear: 20049222123514999052
82. Wenzel J,et al. Hypocretin/orexin increases the expression of steroidogenic enzymes in human adrenocortical NCI H295R cellsAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2009297R1601R160919793950
83. Karteris E,et al. Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortexAm. J. Physiol. Endocrinol. MetabYear: 2005288E1089E110015687100
84. Levin BE,Hogan S,Sullivan AC. Initiation and perpetuation of obesity and obesity resistance in ratsAm. J. PhysiolYear: 1989256R766R7712646957
85. Ricci MR,Levin BE. Ontogeny of diet-induced obesity in selectively bred Sprague-Dawley ratsAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2003285R610R61812775555
86. Levin BE,et al. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley ratsAm.J. PhysiolYear: 1997273R725R7309277561
87. Levin BE,Dunn-Meynell AA. Reduced central leptin sensitivity in rats with diet-induced obesityAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2002283R941R94812228064
88. Clegg DJ,et al. Reduced anorexic effects of insulin in obesity-prone rats fed a moderate-fat dietAm. J. Physiol. Regul. Integr Comp. PhysiolYear: 2005288R981R98615604298
89. Thorpe AJ,Kotz CM. Orexin A in the nucleus accumbens stimulates feeding and locomotor activityBrain ResYear: 2005105015616215979595
90. Teske JA,Billington CJ,Kuskowksi MA,Kotz CM. Spontaneous physical activity protects against fat mass gainInt. J. Obes. (Lond)Year: 2012364603613 doi:10.1038/ijo.2011.108. 21610695
91. Levin BE. Spontaneous motor activity during the development and maintenance of diet-induced obesity in the ratPhysiol. BehavYear: 1991505735811801012
92. Kotz CM,Teske JA,Billington CJ. Neuroregulation of nonexercise activity thermogenesis and obesity resistanceAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2008294R69971018160530
93. Teske JA,Billington CJ,Kotz CM. Hypocretin/orexin and energy expenditureActa Physiol. (Oxf)Year: 201019830331220070282
94. Sweet DC,et al. Feeding response to central orexinsBrain ResYear: 199982153553810064843
95. Thorpe AJ,et al. Peptides that regulate food intake: regional, metabolic, and circadian specificity of lateral hypothalamic orexin A feeding stimulationAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2003284R1409141712736178
96. Teske JA,Kotz CM. Effect of acute and chronic caloric restriction and metabolic glucoprivation on spontaneous physical activity in obesity-prone and obesity-resistant ratsAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2009297R17618419420294
97. Novak CM,Zhang M,Levine JA. Sensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesityBrain ResYear: 20071169576817706946
98. Novak CM,Levine JA. Daily intraparaventricular orexin—A treatment induces weight loss in ratsObesityYear: 2009171493149819343016
99. Mavanji V,et al. Elevated sleep quality and orexin receptor mRNA in obesity-resistant ratsInt. J. ObesYear: 20103415761588
100. Feder ME,et al. Locomotion in response to shifting climate zones: not so fastAnnu. Rev. PhysiolYear: 20107216719020148672
101. Novak CM,et al. Spontaneous activity, economy of activity, and resistance to diet-induced obesity in rats bred for high intrinsic aerobic capacityHormo. BehavYear: 201058355367
102. Novak CM,et al. Endurance capacity, not body size, determines physical activity levels: role of skeletal muscle PEPCKPloS ONEYear: 20094e586919521512
103. Britton SL,Koch LG. Animal genetic models for complex traits of physical capacityExe. Sport Sci. RevYear: 200129714
104. Hagan JJ,et al. Orexin A activates locus coeruleus cell firing and increases arousal in the ratProc. Natl. Acad. Sci. USAYear: 199996109111091610485925
105. Horvath TL,et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic systemJ. Comp. NeurolYear: 199941514515910545156
106. Bourgin P,et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neuronsJ. NeurosciYear: 2000207760776511027239
107. Methippara MM,et al. Effects of lateral preoptic area application of orexin-A on sleep-wakefulnessNeuroreportYear: 2000113423342611095491
108. Adamantidis AR,et al. Neural substrates of awakening probed with optogenetic control of hypocretin neuronsNatureYear: 200745042042417943086
109. Weaver DR. The suprachiasmatic nucleus: a 25-year retrospectiveJ. Biol. RhythmsYear: 1998131001129554572
110. Abrahamson EE,Leak RK,Moore RY. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systemsNeuroreportYear: 20011243544011209963
111. Deurveilher S,Semba K. Indirect projections from the suprachiasmatic nucleus to major arousal-promoting cell groups in rat: implications for the circadian control of behavioural stateNeuroscienceYear: 200513016518315561433
112. Yoshida K,et al. Afferents to the orexin neurons of the rat brainJ. Comp. NeurolYear: 200649484586116374809
113. Martinez GS,Smale L,Nunez AA. Diurnal and nocturnal rodents show rhythms in orexinergic neuronsBrain ResYear: 20029551712419515
114. Zhang S,et al. Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 releaseSleepYear: 20042761962715282996
115. Chemelli RM,et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulationCellYear: 19999843745110481909
116. Estabrooke IV,et al. Fos expression in orexin neurons varies with behavioral stateJ. NeurosciYear: 2001211656166211222656
117. Nixon JP,Smale L. Individual differences in wheel-running rhythms are related to temporal and spatial patterns of activation of orexin A and B cells in a diurnal rodent (Arvicanthis niloticus)NeuroscienceYear: 2004127253415219665
118. Tsunematsu T,et al. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in miceJ. NeurosciYear: 201131105291053921775598
119. Ida T,et al. Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of ratsBrain ResYear: 199982152652910064841
120. Yamanaka A,et al. Hypothalamic orexin neurons regulate arousal according to energy balance in miceNeuronYear: 20033870171312797956
121. Wu MF,et al. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movementAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2002283R1079108612376401
122. Overeem S,et al. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectivesJ. Clin. NeurophysiolYear: 2001187810511435802
123. Siegel JM. Hypocretin (orexin): role in normal behavior and neuropathologyAnnu. Rev. PsycholYear: 20045512514814744212
124. Kiyashchenko LI,et al. Release of hypocretin (orexin) during waking and sleep statesJ. NeurosciYear: 2002225282528612097478
125. Schuld A,et al. Increased body-mass index in patients with narcolepsyLancetYear: 20003551274127510770327
126. Middelkoop HA,et al. Circadian distribution of motor activity and immobility in narcolepsy: assessment with continuous motor activity monitoringPsychophysiologyYear: 1995322862917784537
127. Stamatakis KA,Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjectsChestYear: 20101379510119542260
128. Spiegel K,et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetiteAnn. Intern. MedYear: 200414184685015583226
129. Blanchong JA,et al. Nocturnal and diurnal rhythms in the unstriped Nile rat, Arvicanthis niloticusJ. Biol. RhythmsYear: 19991436437710511004
130. Schwartz MD,Smale L. Individual differences in rhythms of behavioral sleep and its neural substrates in Nile grass ratsJ. Biol. RhythmsYear: 20052052653716275771
131. Donahoo WT,Levine JA,Melanson EL. Variability in energy expenditure and its componentsCurr. Opin. Clin. Nutr. Metab. CareYear: 2004759960515534426
132. Widdowson EM,Edholm OG,Mc CR. The food intake and energy expenditure of cadets in trainingBr. J. NutrYear: 1954814715513160313
133. Zurlo F,et al. Spontaneous physical activity and obesity: cross-sectional and longitudinal studies in Pima IndiansAm. J. PhysiolYear: 1992263E296E3001514610
134. Tou JC,Wade CE. Determinants affecting physical activity levels in animal modelsExp. Biol. MedYear: 2002227587600
135. Hill JO. Can a small-changes approach help address the obesity epidemic? A report of the Joint Task Force of the American Society for Nutrition, Institute of Food Technologists, and International Food Information CouncilAm. J. Clin. NutrYear: 20098947748419088151
136. Leibel RL,Rosenbaum M,Hirsch J. Changes in energy expenditure resulting from altered body weightN. Engl. J. MedYear: 19953326216287632212
137. Berthoud HR,Munzberg H. The lateral hypothalamus as integrator of metabolic and environmental needs: from electrical self-stimulation to opto-geneticsPhysiol. BehavYear: 2011104293921549732
138. Sakurai T,et al. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in miceNeuronYear: 20054629730815848807
139. Kampe J,et al. An anatomic basis for the communication of hypothalamic, cortical and mesolimbic circuitry in the regulation of energy balanceEur. J. NeurosciYear: 20093041543019614751
140. Burt J,et al. Local network regulation of orexin neurons in the lateral hypothalamusAm. J. Physiol. Regul. Integr. Comp. PhysiolYear: 2011301R572R58021697524
141. Eggermann E,et al. The wake-promoting hypocretin-orexin neurons are in an intrinsic state of membrane depolarizationJ. NeurosciYear: 2003231557156212629156
142. Winsky-Sommerer R,et al. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress responseJ. NeurosciYear: 200424114391144815601950
143. Williams RH,et al. Adaptive sugar sensors in hypothalamic feeding circuitsProc. Natl. Acad. Sci. USAYear: 2008105119751198018695235
144. Moriguchi T,et al. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemiaNeurosci. LettYear: 199926410110410320024
145. Cai XJ,et al. Hypothalamic orexin expression: modulation by blood glucose and feedingDiabetesYear: 1999482132213710535445
146. Silva JP,et al. Regulation of adaptive behaviour during fasting by hypothalamic Foxa2NatureYear: 200946264665019956259
147. Louis GW,et al. Direct innervation and modulation of orexin neurons by lateral hypothalamic LepRb neuronsJ. NeurosciYear: 201030112781128720739548
148. Karnani MM,et al. Activation of central orexin/hypocretin neurons by dietary amino acidsNeuronYear: 20117261662922099463
149. Acuna-Goycolea C,van den Pol A. Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousalJ. NeurosciYear: 2004248141815215371515
150. Malisch JL,et al. Behavioral despair and home-cage activity in mice with chronically elevated baseline corticosterone concentrationsBehav. GenetYear: 20093919220119067154

Figures

[Figure ID: fig01]
Figure 1 

Difference in orexin 2 receptor (OX2R) protein levels between obesity-prone (OP) and obesity-resistant (OR) rats on chow diet. (A) Western blot analysis of caudal lateral hypothalamus (cLH) of OP and OR rats. The 52–53 kDA band is the predicted size of OXR2. Samples were normalized to β-actin. (B) Densitometric analysis of the Western blot data for all OP and OR rats. N = 4/group; *P < 0.05.



[Figure ID: fig02]
Figure 2 

Total active wake (A) and slow wave sleep (B), in seconds, for obesity-prone (OP) and obesty-resistant (OR) rats for a 2-h period after treatment with vehicle or 500 pmol orexin A (OXA). In both panels, there is a significant overall effect of OXA on increasing active wake (P = 0.0004) and decreasing quiet sleep (P = 0.0039), respectively. However, there is no difference for either wake or sleep between OP and OR rats within treatment groups, despite the fact that OR rats show significantly higher levels of spontaneous physical activity following OXA treatment. N = 6/group; data are means ± SEM. **P < 0.005; ***P < 0.0005.



[Figure ID: fig03]
Figure 3 

Overview of the involvement of orexin in a neural network regulating nonexercise activity thermogenesis (NEAT), indicating a sample of the brain areas, neuropeptides, and transmitters involved. Colors correspond to specific neuropeptide/hormone as follows: Black circles/projections: orexin; green, dopamine; orange, serotonin; pink, histamine; blue, norepinephrine; brown, neuropeptide Y/agouti-related protein (NPY/AgRP) and proopiomelanocortin/cocaine and amphetamine-related transcript (POMC/CART). Signals from all of these areas have the potential to influence cortical premotor neurons (indicated by arrows), and feedback from premotor neurons and orexinergic projections may interact to drive SPA. See the text for details. CCK, cholecystokinin; DR, dorsal raphe; LC, locus coeruleus; LH, lateral hypothalamus; NAccSH, shell of nucleus accumbens; NMU, neuromedin U; PVN, hypothalamic paraventricular nucleus; VTA, ventral tegmental area; rLH, rostral LH; SN, substantia nigra; TMN, tuberomammillary nucleus. Brain areas are not all to scale, and connections and neuropeptides/transmitters indicated are not all inclusive. Not all connections shown are discussed in this review. Figure modified from work by Kotz et al.92



Article Categories:
  • Original Articles

Keywords: orexin, obesity, spontaneous physical activity, nonexercise activity thermogenesis, energy expenditure.

Previous Document:  Continuous flow reactor for production of stable amyloid protein oligomers.
Next Document:  Genetic aspects of sodium channelopathy in small fiber neuropathy.